Related Experiment Video
Updated: Aug 6, 2026
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents
Roland W Freudenmann1, Florian Oxler, Sabine Bernschneider-Reif
1Department of Psychiatry, University of Ulm, Leimgrubenweg 12, 89075 Ulm, Germany. roland.freudenmann@uni-ulm.de
Background:
Little is known about the origin of methylenedioxymethamphetamine (MDMA, ecstasy). The most commonly repeated statement in the medical literature is that MDMA was synthesized by the German pharmaceutical company Merck in 1912 in order to develop an appetite suppressor.
Aim:
To reconstruct the true story of the first known description of MDMA at Merck using the original documents.
Methods:
A systematic analysis of the original documents in Merck's historical archive in Darmstadt, Germany, was conducted (years 1900-60).
Results:
There were no indications for plans to develop an appetite suppressant at Merck between 1900 and 1960. Although MDMA was, in fact, first synthesized at Merck in 1912, it was not tested pharmacologically because it was only an unimportant precursor in a new synthesis for haemostatic substances. The new pathway was patented in order to evade an existing patent by a local competitor. MDMA was called "Methylsafrylamin" in 1912. In 1927 and 1959, the pharmacological effects of MDMA were studied at Merck, but not in humans.
Discussion:
A systematic analysis of the original documents in the company's archive revealed that uncritical copy-paste procedures may have contributed to the famous myth that MDMA was patented as an appetite suppressor in 1912.
Related Concept Videos
01:17Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
01:18Effects of EDTA on End-Point Detection Methods
In the visual method, metal-ion indicators (metallochromic dyes), which have distinct colors in their free and complex forms, are added to the mixture to signal the titration's end point. They form stable complexes with metal ions, but these complexes are weaker than the corresponding metal–EDTA complexes. As a result, EDTA...